BACKGROUND: Atrial fibrosis concurs with chronic atrial fibrillation (AF), a phenomenon that contributes to the resistance to restore and maintain sinus rhythm (SR). Fibrogenesis represents a complex process in which the transforming growth factor-β1 (TGF-β1) pathway may play a major role, e.g. in the setting of myocardial infarction. The present study addresses the potential contribution of the TGF-β1 signaling pathway to atrial fibrosis in patients with AF. METHODS AND RESULTS: Right atrial appendages of 163 patients were excised during heart surgery and grouped according to rhythm (SR vs. AF) and AF duration. Five groups were defined: SR, paroxysmal/chronic persistent AF (<6 months), chronic permanent AF (CAF) of 7-24 months, 25-60 months, and >60 months duration. Collagen content of atria, determined morphometrically, revealed a steady and significant increase in patients with SR (14.6±8.9%) up to patients with CAF of >60 months (28.1±7.1%). Likewise, expression of TGF-β1 mRNA and protein, TGF-β-receptor-II protein, profibrotic phospho-Smad-2 and -4 proteins increased. However, the TGF-β(1) effect appeared to decline with increasing AF duration, characterized by a decrease in TGF-β-receptor-I protein, increases of TGF-β inhibiting Smad-7 protein and a reduction of ph-Smad-2. CONCLUSIONS: Human atrial fibrogenesis in patients with atrial fibrillation is accompanied by a biphasic response, an early increase and later loss of responsiveness to TGF-β(1). It appears that fibrosis progresses despite compensatory changes in the TGF-β-signaling pathway. The sequential changes in the contribution of different profibrotic processes during the establishment of AF may offer the opportunity to selectively interfere with the atrial remodeling process at different stages.
BACKGROUND:Atrial fibrosis concurs with chronic atrial fibrillation (AF), a phenomenon that contributes to the resistance to restore and maintain sinus rhythm (SR). Fibrogenesis represents a complex process in which the transforming growth factor-β1 (TGF-β1) pathway may play a major role, e.g. in the setting of myocardial infarction. The present study addresses the potential contribution of the TGF-β1 signaling pathway to atrial fibrosis in patients with AF. METHODS AND RESULTS: Right atrial appendages of 163 patients were excised during heart surgery and grouped according to rhythm (SR vs. AF) and AF duration. Five groups were defined: SR, paroxysmal/chronic persistent AF (<6 months), chronic permanent AF (CAF) of 7-24 months, 25-60 months, and >60 months duration. Collagen content of atria, determined morphometrically, revealed a steady and significant increase in patients with SR (14.6±8.9%) up to patients with CAF of >60 months (28.1±7.1%). Likewise, expression of TGF-β1 mRNA and protein, TGF-β-receptor-II protein, profibrotic phospho-Smad-2 and -4 proteins increased. However, the TGF-β(1) effect appeared to decline with increasing AF duration, characterized by a decrease in TGF-β-receptor-I protein, increases of TGF-β inhibiting Smad-7 protein and a reduction of ph-Smad-2. CONCLUSIONS:Human atrial fibrogenesis in patients with atrial fibrillation is accompanied by a biphasic response, an early increase and later loss of responsiveness to TGF-β(1). It appears that fibrosis progresses despite compensatory changes in the TGF-β-signaling pathway. The sequential changes in the contribution of different profibrotic processes during the establishment of AF may offer the opportunity to selectively interfere with the atrial remodeling process at different stages.
Authors: Gintas P Krisciunas; Kerlly Castellano; Timothy M McCulloch; Cathy L Lazarus; Barbara R Pauloski; Tanya K Meyer; Darlene Graner; Douglas J Van Daele; Alice K Silbergleit; Lisa R Crujido; Denis Rybin; Gheorghe Doros; Tamar Kotz; Susan E Langmore Journal: Dysphagia Date: 2016-11-16 Impact factor: 3.438
Authors: Mohit K Turagam; Mahek Mirza; Paul H Werner; Jasbir Sra; David C Kress; A Jamil Tajik; Arshad Jahangir Journal: Cardiol Rev Date: 2016 Mar-Apr Impact factor: 2.644
Authors: Irina A Polejaeva; Ravi Ranjan; Christopher J Davies; Misha Regouski; Justin Hall; Aaron L Olsen; Qinggang Meng; Heloisa M Rutigliano; Derek J Dosdall; Nathan A Angel; Frank B Sachse; Thomas Seidel; Aaron J Thomas; Rusty Stott; Kip E Panter; Pamela M Lee; Arnaud J Van Wettere; John R Stevens; Zhongde Wang; Rob S MacLeod; Nassir F Marrouche; Kenneth L White Journal: J Cardiovasc Electrophysiol Date: 2016-08-30
Authors: Philippe Chetaille; Christoph Preuss; Silja Burkhard; Jean-Marc Côté; Christine Houde; Julie Castilloux; Jessica Piché; Natacha Gosset; Séverine Leclerc; Florian Wünnemann; Maryse Thibeault; Carmen Gagnon; Antonella Galli; Elizabeth Tuck; Gilles R Hickson; Nour El Amine; Ines Boufaied; Emmanuelle Lemyre; Pascal de Santa Barbara; Sandrine Faure; Anders Jonzon; Michel Cameron; Harry C Dietz; Elena Gallo-McFarlane; D Woodrow Benson; Claudia Moreau; Damian Labuda; Shing H Zhan; Yaoqing Shen; Michèle Jomphe; Steven J M Jones; Jeroen Bakkers; Gregor Andelfinger Journal: Nat Genet Date: 2014-10-05 Impact factor: 38.330